



RESET Myositis™

A clinical trial exploring the potential of cell therapy in myositis

The RESET-Myositis™ study is evaluating the safety, tolerability and effectiveness of the investigational treatment CABA-201 in adult and juvenile patients with myositis

Personalized therapy

CABA-201 is an investigational CAR T therapy that uses the power of your own immune system to target the cells that may be causing your disease.

One-time infusion

Your CABA-201 cells will be delivered as a one-time treatment.

Study support

Participants receive study-related care at no cost and may receive compensation for time and travel.

The potential risks of participating in this trial will be explained before you decide whether to participate.

You or someone you know may be able to participate if you meet the following criteria:



Adult: 18 to 75 years of age with anti-synthetase syndrome, dermatomyositis, or immune-mediated necrotizing myopathy



Juvenile: 6 to 17 years of age with a diagnosis of myositis



Have at least one myositis autoantibody



Have active disease despite being on medications to treat myositis

Additional eligibility requirements will apply, and only a study doctor can determine eligibility to participate

**Find study site
contact information**

<https://clinicaltrials.gov/study/NCT06154252>

**Learn more about
RESET-Myositis™**

www.reset-myositis-trial.com